News

Belarus is the 21st country to approve the company’s Phase III trial, which is now enrolling patients with advanced primary, not yet treated, head and neck cancer. CEL-SCI

The trial, which evaluated the safety, efficacy and pharmacokinetics of Alprolix, met its primary endpoint and achieved low bleeding rates with once-weekly prophylactic dosing in children. Alprolix is

The acquired business has been reorganized under Mylan N.V., a new public company organized in the Netherlands, which will be led by the former Mylan executive team. As

The partnership between the firms will allow women, regardless of income and insurance coverage, to access this new and effective contraceptive option. Liletta is a small, flexible plastic

The agency also granted priority review for this BLA and has given the Prescription Drug User Fee Act (PDUFA) goal date of 22 June 2015 for a decision.

Standard chemotherapy includes paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan for patients who cannot receive platinum therapy. Cervical cancer is most commonly diagnosed in women aged between

If Zykadia receives approval in the European Union (EU), it will be the first treatment option to address an unmet medical need for these patients. Zykadia is an

To be launched in Germany, Italy, the UK, Netherlands, Belgium and Luxembourg, Remsima is authorised for the treatment of patients with Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing

The company said that TRPH 011 binds and neutralizes VEGFR-2/KDR and TIE 2 receptors simultaneously, resulting in sustained inhibition of tumor growth and angiogenesis. Angiogenesis is the formation